• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎:康复或死亡的新兴免疫病理决定因素

COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

作者信息

Ahmad Tanveer, Chaudhuri Rituparna, Joshi Mohan C, Almatroudi Ahmad, Rahmani Arshad Husain, Ali Syed Mansoor

机构信息

Multidisciplinary Centre for Advanced Research and Studies, Jamia Millia Islamia, New Delhi, India.

Department of Molecular and Cellular Neuroscience, Neurovirology Section, National Brain Research Centre (NBRC), Haryana, India.

出版信息

Front Microbiol. 2020 Dec 1;11:588409. doi: 10.3389/fmicb.2020.588409. eCollection 2020.

DOI:10.3389/fmicb.2020.588409
PMID:33335518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7736111/
Abstract

Hyperactivation of the host immune system during infection by SARS-CoV-2 is the leading cause of death in COVID-19 patients. It is also evident that patients who develop mild/moderate symptoms and successfully recover display functional and well-regulated immune response. Whereas a delayed initial interferon response is associated with severe disease outcome and can be the tipping point towards immunopathological deterioration, often preceding death in COVID-19 patients. Further, adaptive immune response during COVID-19 is heterogeneous and poorly understood. At the same time, some studies suggest activated T and B cell response in severe and critically ill patients and the presence of SARS-CoV2-specific antibodies. Thus, understanding this problem and the underlying molecular pathways implicated in host immune function/dysfunction is imperative to devise effective therapeutic interventions. In this comprehensive review, we discuss the emerging immunopathological determinants and the mechanism of virus evasion by the host cell immune system. Using the knowledge gained from previous respiratory viruses and the emerging clinical and molecular findings on SARS-CoV-2, we have tried to provide a holistic understanding of the host innate and adaptive immune response that may determine disease outcome. Considering the critical role of the adaptive immune system during the viral clearance, we have presented the molecular insights of the plausible mechanisms involved in impaired T cell function/dysfunction during various stages of COVID-19.

摘要

在SARS-CoV-2感染期间宿主免疫系统的过度激活是COVID-19患者死亡的主要原因。同样明显的是,出现轻/中度症状并成功康复的患者表现出功能正常且调节良好的免疫反应。而初始干扰素反应延迟与严重疾病结局相关,并且可能是免疫病理恶化的转折点,通常先于COVID-19患者死亡。此外,COVID-19期间的适应性免疫反应具有异质性且了解甚少。同时,一些研究表明重症和危重症患者存在活化的T细胞和B细胞反应以及SARS-CoV-2特异性抗体。因此,了解这个问题以及宿主免疫功能/功能障碍所涉及的潜在分子途径对于设计有效的治疗干预措施至关重要。在这篇全面综述中,我们讨论了新出现的免疫病理决定因素以及宿主细胞免疫系统逃避病毒的机制。利用从先前呼吸道病毒获得的知识以及关于SARS-CoV-2的新出现的临床和分子发现,我们试图全面了解可能决定疾病结局的宿主固有和适应性免疫反应。考虑到适应性免疫系统在病毒清除过程中的关键作用,我们阐述了COVID-19各个阶段T细胞功能受损/功能障碍所涉及的可能机制的分子见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/954e366e5f24/fmicb-11-588409-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/76205165bee7/fmicb-11-588409-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/ee8265f28f91/fmicb-11-588409-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/06c073366771/fmicb-11-588409-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/0e0828ebea99/fmicb-11-588409-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/954e366e5f24/fmicb-11-588409-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/76205165bee7/fmicb-11-588409-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/ee8265f28f91/fmicb-11-588409-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/06c073366771/fmicb-11-588409-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/0e0828ebea99/fmicb-11-588409-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2e/7736111/954e366e5f24/fmicb-11-588409-g005.jpg

相似文献

1
COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.新型冠状病毒肺炎:康复或死亡的新兴免疫病理决定因素
Front Microbiol. 2020 Dec 1;11:588409. doi: 10.3389/fmicb.2020.588409. eCollection 2020.
2
Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases.宿主对 SARS-CoV2 及现有肝脏和胃肠道疾病中新兴变异株的反应。
Front Cell Infect Microbiol. 2021 Oct 25;11:753249. doi: 10.3389/fcimb.2021.753249. eCollection 2021.
3
Human Nasal and Lung Tissues Infected with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract.人鼻腔和肺部组织感染 SARS-CoV-2 提供了在上呼吸道和下呼吸道中不同组织特异性和病毒特异性先天免疫反应的见解。
J Virol. 2021 Jun 24;95(14):e0013021. doi: 10.1128/JVI.00130-21.
4
A review on the immune responses against novel emerging coronavirus (SARS-CoV-2).新型冠状病毒(SARS-CoV-2)免疫反应综述。
Immunol Res. 2021 Jun;69(3):213-224. doi: 10.1007/s12026-021-09198-0. Epub 2021 Apr 29.
5
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
6
SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.严重和致命的新型冠状病毒肺炎(COVID-19)中,原发性抗体缺陷患者无特异性体液免疫时的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)T细胞反应
Front Immunol. 2022 Mar 10;13:840126. doi: 10.3389/fimmu.2022.840126. eCollection 2022.
7
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors.固有免疫和适应性免疫对 SARS-CoV-2 及相关影响因素。
Front Immunol. 2023 May 9;14:1159326. doi: 10.3389/fimmu.2023.1159326. eCollection 2023.
8
SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells.德尔塔变异株 SARS-CoV-2 强烈抑制先天免疫反应并逃避人结肠上皮细胞中干扰素激活的抗病毒反应。
Microbiol Spectr. 2022 Oct 26;10(5):e0160422. doi: 10.1128/spectrum.01604-22. Epub 2022 Sep 8.
9
Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived)为农村及服务欠缺地区的冠状病毒病(COVID-19)患者提供单克隆抗体治疗(存档)
10
SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?SARS-CoV-2 逃避干扰素系统:我们能否恢复其有效性?
Int J Mol Sci. 2023 May 27;24(11):9353. doi: 10.3390/ijms24119353.

引用本文的文献

1
Association of zinc deficiency and clinical symptoms, inflammatory markers, severity of COVID-19 in hospitalized children.住院儿童锌缺乏与临床症状、炎症标志物、新冠病毒疾病严重程度的关联
Front Nutr. 2025 Mar 25;12:1566505. doi: 10.3389/fnut.2025.1566505. eCollection 2025.
2
Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients.新冠康复患者中与结节病相关的自身免疫性炎症
Front Med (Lausanne). 2023 Dec 21;10:1271198. doi: 10.3389/fmed.2023.1271198. eCollection 2023.
3
Biomarkers of sequela in adult patients convalescing from COVID-19.

本文引用的文献

1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.致病性T细胞和炎性单核细胞在重症COVID-19患者中引发炎症风暴。
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes.前沿科学:COVID-19 感染可诱导外周血单核细胞中易于检测到的形态和炎症相关表型变化。
J Leukoc Biol. 2021 Jan;109(1):13-22. doi: 10.1002/JLB.4HI0720-470R. Epub 2020 Oct 11.
3
Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19.
COVID-19康复期成年患者后遗症的生物标志物
Adv Biomark Sci Technol. 2022;4:36-53. doi: 10.1016/j.abst.2022.10.001. Epub 2022 Nov 9.
4
NSP4 and ORF9b of SARS-CoV-2 Induce Pro-Inflammatory Mitochondrial DNA Release in Inner Membrane-Derived Vesicles.SARS-CoV-2 的 NSP4 和 ORF9b 诱导内膜衍生囊泡中促炎线粒体 DNA 的释放。
Cells. 2022 Sep 23;11(19):2969. doi: 10.3390/cells11192969.
5
Reliability of predictive models to support early decision making in the emergency department for patients with confirmed diagnosis of COVID-19: the Pescara Covid Hospital score.用于支持确诊 COVID-19 患者在急诊科早期决策的预测模型的可靠性:佩斯卡拉 COVID 医院评分。
BMC Health Serv Res. 2022 Aug 19;22(1):1062. doi: 10.1186/s12913-022-08421-4.
6
Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade.严重急性呼吸综合征冠状病毒2感染:白细胞介素-6及炎症级联反应的作用
World J Virol. 2022 May 25;11(3):113-128. doi: 10.5501/wjv.v11.i3.113.
7
Immune-Mediated Inflammatory Responses of Alveolar Epithelial Cells: Implications for COVID-19 Lung Pathology.肺泡上皮细胞的免疫介导炎症反应:对COVID-19肺部病理学的影响
Biomedicines. 2022 Mar 7;10(3):618. doi: 10.3390/biomedicines10030618.
8
Post-acute sequelae of COVID-19: A metabolic perspective.新型冠状病毒肺炎的远期后遗症:代谢角度的观察。
Elife. 2022 Mar 23;11:e78200. doi: 10.7554/eLife.78200.
9
Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern.2019冠状病毒病疫苗及其他治疗干预措施的分子与临床方面:关于新出现的值得关注的变异株
Front Pharmacol. 2021 Dec 23;12:778219. doi: 10.3389/fphar.2021.778219. eCollection 2021.
10
HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis.HeberNasvac,一种用于慢性乙型肝炎的治疗性疫苗,可刺激先天免疫的局部和全身标志物:在SARS-CoV-2暴露后预防中的潜在用途。
Euroasian J Hepatogastroenterol. 2021 Jul-Dec;11(2):59-70. doi: 10.5005/jp-journals-10018-1344.
滤泡外 B 细胞反应与 COVID-19 中的中和抗体和发病相关。
Nat Immunol. 2020 Dec;21(12):1506-1516. doi: 10.1038/s41590-020-00814-z. Epub 2020 Oct 7.
4
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.无症状或轻症 COVID-19 康复者体内具有强大的 T 细胞免疫。
Cell. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14.
5
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.COVID-19 危重症患者体内针对 I 型干扰素的自身抗体。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.
6
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.COVID-19 危重症患者的 I 型 IFN 免疫先天缺陷。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4570. Epub 2020 Sep 24.
7
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.冠状病毒抗体介导免疫的系统评价:动力学、保护相关性及与严重程度的关系。
Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4.
8
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant.SARS-CoV-2 ORF3b 是一种有效的干扰素拮抗剂,其活性可被一种自然发生的延长变异体增强。
Cell Rep. 2020 Sep 22;32(12):108185. doi: 10.1016/j.celrep.2020.108185. Epub 2020 Sep 4.
9
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.I 型干扰素易感性区分 SARS-CoV-2 和 SARS-CoV。
J Virol. 2020 Nov 9;94(23). doi: 10.1128/JVI.01410-20.
10
Seasonal coronavirus protective immunity is short-lasting.季节性冠状病毒的保护免疫作用是短暂的。
Nat Med. 2020 Nov;26(11):1691-1693. doi: 10.1038/s41591-020-1083-1. Epub 2020 Sep 14.